Saturday, March 15, 2025
1.9 C
London
HomeFinTechPharmAust: Gets approval to increase dosage in MPL trial

PharmAust: Gets approval to increase dosage in MPL trial

Date:

ABN AMRO-Owned Neobroker Fined $1.6M for Paying Finfluencers

A Significant Penalty in the Financial Industry Highlights Regulatory...

AvidXchange Explores Potential Sale Amid Market Changes

What Investors Need to Know About AvidXchange's Strategic ShiftHighlights:...

Raisin Expands Its Offerings by Launching in Finland

Discover how Raisin is transforming the financial landscape in...

PharmAust Gets approval to increase dosage in MPL trial

  • PharmAust (PAA) has received the green light from the trial safety committee to increase the tablet dosage in its motor neurone disease study
  • The company reported no safety issues or serious adverse events found during its study, as a result of the treatment
  • The company says it will continue supplying MPL tablets to all six patients in cohort one, with a four-week escalating dose of the MPL tablets set to begin
  • Patient recruitment for the next stage MPL dosing level has started, with four new patients currently undergoing screening
  • The company shares were up 1.15 per cent, trading at 8.8 cents at 1:15 pm AEDT

Related stories

spot_img

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories